目的：观察药物联合正念认知治疗（MBCT）对精神分裂症患者自我怜悯水平及病耻感的影响。方法： 我院收治的精神分裂症患者80例随机分为药物组和联合组，各40例。药物组给予常规药物治疗；联合组增 加MBCT治疗，疗程8周。于治疗前、后，采用中文版自我怜悯量表（SCS-C）评估患者的怜悯感；采用Link 病耻感量表评估患者的病耻感。结果：治疗前，2组的SCS-C和Link病耻量表各项评分差异无统计学意义 （P＞0.05）。治疗后，联合组的SCS-C各项评分均高于同组治疗前（均P＜0.05），药物组各项评分与治疗前 差异无统计学意义（均P＞0.05）；治疗后，联合组SCS-C总分、自我友善和正念得分高于药物组（均P＜0.05）， 2组的普遍人性得分无统计学意义（P＞0.05）。治疗后，联合组的Link病耻量表各项评分均低于同组治疗前 （均P＜0.05），药物组各项评分与治疗前差异无统计学意义（均P＞0.05）；治疗后，联合组Link病耻量表各项 得分低于药物组（均P＜0.05）。结论：MBCT有助于改善精神分裂症患者病耻感并提高患者自我怜悯水平。

To investigate the effect of drug therapy combined with mindfulness-based cognitive therapy (MBCT) on the self-compassion and stigma of schizophrenia patients. Methods：We selected 80 patients with schizophrenia receiving treatment at our hospital for this study. Patients were randomly divided into the drug group and combined group, with 40 cases in each group. Both groups were given conventional drug treatment, and on this basis, the combined group was treated with mindfulness-based cognitive therapy for 8 weeks. The self-compassion scale, Chinese version (SCS-C) and Link Stigma Scale were used to evaluate patients before and after intervention. Results：The SCS-C and Link Stigma Scale scores of the two groups before intervention were not significantly different (P>0.05). After treatment, the combined group showed an increase in all SCS-C item scores compared to before treatment (all P<0.05); the drug group showed no significant difference in scores after treatment compared to before (all P>0.05). The post-treatment SCS-C total score, self-friendliness, and mindfulness scores in the combined group were significantly higher than those of the drug group (all P<0.05); there was no significant difference in common humanity score between the two groups (P> 0.05). After intervention, the Link stigma item scores of the combined group were reduced compared to before intervention (all P<0.05); the drug group scores showed no significant difference before and after treatment (all P>0.05). The post-treatment Link stigma item scores of the combined group were significantly lower than those of the drug group (all P<0.05). Conclusion：MBCT can lessen stigma and improve self-compassion in patients with schizophrenia.